Parmax Pharma Ltd

Parmax Pharma Limited has announced its 32nd Annual General Meeting (AGM) scheduled for Tuesday, September 29, 2026, at 3:30 PM IST. The meeting will be conducted via Video Conferencing/Other Audio Visual Means. Key dates for e-voting include a cut-off date of September 22, 2026, with remote e-voting open from September 26 to September 28, 2026. The AGM agenda includes the adoption of the audited standalone financial statements for FY 2025-26, re-appointment of Shri Umang Gosalia as Director, and the appointment of Mr. Dhiren Chandulal Shah and Mr. Sunil Chinubhai Shah as Non-Executive Directors.

Parmax Pharma Limited has released its Annual Report for the Financial Year 2025-26 and the Notice for its 32nd Annual General Meeting (AGM). The AGM is scheduled for September 29, 2026, to be held via Video Conference. Key agenda items include the adoption of audited standalone financial statements for FY26 and the re-appointment of Shri Umang Gosalia as Director. Additionally, Mr. Dhiren Chandulal Shah is proposed for appointment as a Non-Executive Director and Chairman. The report also details corporate information, board composition, and auditor details.

Parmax Pharma Ltd has filed a disclosure under SEBI (Substantial Acquisition of Shares & Takeovers) Regulations, 2011, detailing changes in shareholding by Dhiren Shah and Persons Acting in Concert (PACs). The acquirers and PACs, considered part of the promoter group, have acquired 22,80,444 equity shares and 17,16,574 warrants pursuant to a preferential issue. This acquisition, approved by BSE, has altered their total holding. The filing provides a detailed breakdown of share and warrant acquisition before and after the transaction, impacting their overall stake in the company.

Parmax Pharma Ltd announced the allotment of 31,37,586 equity shares and 21,45,145 convertible warrants on a preferential basis to non-promoter category individuals. The equity shares were allotted at an issue price of ₹36.50 each, including a premium of ₹26.50. The convertible warrants are also priced at ₹36.50 each and are convertible into one equity share within 18 months. The total funds raised from the equity share allotment amount to ₹11,45,21,889. The company received in-principle approval from the stock exchange on August 21, 2026.

Parmax Pharma Limited has filed an intimation regarding the reclassification of its promoters under Regulation 31A of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015. Following an Open Offer and a Share Purchase Agreement, certain individuals and entities will be classified as new promoters and promoter group members, while the erstwhile promoters will be reclassified under the Public Category. This move is in compliance with SEBI regulations, with undertakings provided by the parties involved confirming adherence to the stipulated conditions for reclassification.

Parmax Pharma Ltd has received 'In-Principle' Approval from BSE Limited for the issuance of equity shares and warrants on a preferential basis. The approval, granted under Regulation 28(1) of SEBI LODR Regulations, permits the issuance of 31,37,586 equity shares at a price of not less than ₹36.50 per share and 21,45,145 warrants convertible into equity shares at a price of not less than ₹36.50 per warrant. This approval is contingent upon compliance with applicable SEBI regulations. The company had previously intimated about this proposed issuance on June 8, 2026.

Alkesh Mahasukhlal Gopani, Vipul Mahasukhlal Gopani, and Pravina Mahasukh Gopani have collectively sold 11,52,450 equity shares of Parmax Pharma Limited. The transaction, representing 30.81% of the total diluted share capital, occurred on August 13, 2026, via an off-market share purchase agreement dated June 08, 2026. This disclosure is made in compliance with SEBI (Substantial Acquisition of Shares & Takeovers) Regulations, 2011.

Dhiren Chandulal Shah, Sunil Chinubhai Shah, and Persons Acting in Concert (PACs) have acquired 11,52,450 equity shares of Parmax Pharma Limited, representing 30.81% of the total share capital. This acquisition, made off-market on August 13, 2026, pursuant to a Share Purchase Agreement dated June 08, 2026, increases their total holding to 58.01%. The transaction was disclosed under Regulation 29(2) of the SEBI (Substantial Acquisition of Shares & Takeovers) Regulations, 2011. The total equity share capital of Parmax Pharma remains at ₹3,74,13,000.

Parmax Pharma Ltd announced board changes following a meeting on August 14, 2026. Mr. Dhiren Shah and Mr. Sunil Shah were appointed as Additional Directors (Non-Executive). The board also recommended Ms. Anjana Shah and Mr. Ashish Shah as Non-Executive Independent Directors for a term of 5 years, subject to shareholder approval at the upcoming AGM. Additionally, Ms. Salma Thobhani resigned as a non-executive director. The company also approved the Unaudited Financial Results for the quarter ended June 30, 2026, along with the Limited Review Report. All newly appointed directors have confirmed they are not debarred from holding office.

Parmax Pharma Ltd announced that its Board of Directors, in a meeting held on August 14, 2026, approved the unaudited financial results for the quarter ended June 30, 2026. The board also approved the appointment of Mr. Dhiren Chandulal Shah as Additional Director – Non-Executive and Chairman, and Mr. Sunil Shah as Additional Director - Non-Executive. Additionally, the appointment of Mrs. Anjana Paresh Shah and Mr. Ashish Atmaram Shah as Non-Executive Independent Directors for 5 years was recommended for the upcoming AGM. Ms. Salma Thobhani resigned as a non-executive director.